Theranos investor-fraud case

Summary

What the record shows

Theranos promoted technology that it said could perform many blood tests from a very small sample. The Securities and Exchange Commission charged that the company and its leaders raised more than $700 million while making false or exaggerated statements about the technology, business and financial performance.

A jury convicted Elizabeth Holmes of one investor-fraud conspiracy count and three wire-fraud counts. She was sentenced to 135 months in prison. Ramesh “Sunny” Balwani was convicted separately and sentenced to 155 months. Their convictions were upheld on appeal in 2025.

Key findings

What is established and what is not

Holmes’s convictions concern fraud against investors and are supported by a criminal judgment that survived appellate review.
The jury acquitted Holmes on the patient-related conspiracy count and on three patient-related fraud counts; it did not reach a verdict on three additional investor counts.
Balwani was tried separately and convicted on all counts presented in his trial.

Response and denials

The other side of the record

Holmes contested the criminal allegations, pleaded not guilty and argued on appeal that evidentiary and trial errors required a new trial.

The Ninth Circuit rejected the appeal and affirmed the convictions. Subsequent reporting has noted that Holmes continues to maintain her innocence.

Global Scam Report evaluation

Summary assessment

Court-established investor fraud — very high confidence. Care is required not to overstate the verdict: Holmes was not convicted on the patient-related counts, even though patient impact and testing reliability were extensively examined in regulatory and trial records.

Scope qualificationThis profile reports the actual split verdict and does not attribute every operational failure at Theranos to every employee, clinician or investor.

Reference record